Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer

The occurrence of thyroid cancer has been increasing in the United States. For some patients, with particularly advanced and metastatic cancer, current treatments such as thyroidectomy and adjuvant radioactive iodine therapy can lead to poor outcomes. Hence, there is a need for new thyroid cancer treatments.

Researchers at the NCI have developed novel T-cell receptors (TCRs) to target thyroid cancer. They immunized HLA-A2+ transgenic mice to generate TCRs that recognize human thyroglobulin (TG). TG, a tissue-differentiation antigen, is only expressed in thyroid cancer and normal thyroid tissues. The anti-TG TCRs can be expressed in a patient’s peripheral blood lymphocytes as part of adoptive cell therapy (ACT) to treat cancer. This discovery, along with hormonal therapy to replace normal thyroid function, can be used to eradicate tumor cells. 
The National Cancer Institute, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize novel T-cell receptors for the treatment of metastatic thyroid cancer.

Potential Commercial Applications: Competitive Advantages:
  • Immunotherapy for metastatic thyroid cancer
  • Target specificity due to tissue-differentiation antigen that is only expressed in the thyroid
  • Alternative treatment for patients with metastatic thyroid cancer that is resistant to the current standard of care

Development Stage:
Pre-clinical (in vivo)

Related Invention(s):


Kenichi Hanada (NCI)  ➽ more inventions...

Qiong Wang (NCI)  ➽ more inventions...

Zhiya Yu (NCI)  ➽ more inventions...

James Yang (NCI)  ➽ more inventions...

Intellectual Property:
Application No. 62/079,713
Application No. PCT/US2015/060282 

Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells  PMID 22160384
Kloos RT, Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer  PMID 18463349

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-226-2014
Updated: May 16, 2018